Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Trials
100%
Sample Size Calculation
61%
Co-primary
55%
Co-primary Endpoints
42%
Meta-analysis
29%
Thymoma
29%
Prognostic Factors
21%
Randomized Controlled Trial
21%
Aortic Stenosis
20%
Type 2 Diabetic Patients
19%
Confidence Interval
17%
Statins
15%
Local Lymph Node Assay
15%
Correlated Endpoints
14%
Coronary Computed Tomography Angiography
14%
Fractional Flow Reserve
14%
Principal Coordinate Analysis (PCoA)
14%
NK Cell Activity
14%
Ph+ Leukemia
14%
Dasatinib
14%
Cytomegalovirus
14%
Japan
14%
Multiple Primary Endpoints
14%
Validation Studies
13%
FFRCT
12%
Binary Variables
12%
Coronary Artery Plaque
12%
Alogliptin
12%
Odds Ratio
11%
Intravascular Ultrasound
11%
Time-to-event Outcomes
11%
Individual Power
11%
Group Sequential Design
11%
Overall Survival
11%
Warfarin
11%
Plaque Composition
10%
Time-to-event Endpoint
10%
95% Confidence Interval
10%
Thymus
10%
Cardiovascular Events
10%
Multiple Endpoints
10%
Required Sample Size
10%
Inter-laboratory Validation
9%
Systematic Meta-analysis
9%
Risk Factors
9%
Eye Irritation
9%
Idiopathic Inflammatory Myopathies
9%
Interstitial Lung Disease
9%
Thymic Epithelial Tumors
9%
Standardized Mean Difference
9%
Medicine and Dentistry
Meta-Analysis
44%
Thymus Cancer
34%
Prognostic Factor
32%
Systematic Review
30%
Clinical Trial
21%
Statin
19%
Interstitial Lung Disease
19%
Myositis
19%
Odds Ratio
16%
Intravascular Ultrasound
16%
Randomized Controlled Trial
15%
Patient with Type 2 Diabetes
14%
Fractional Flow Reserve
14%
Coronary Computed Tomography Angiography
14%
Overall Survival
12%
Recurrent Disease
11%
Coronary Atherosclerosis
11%
Arteriosclerotic Heart Disease
11%
Diseases
11%
Breast Cancer
11%
Coronary Artery
11%
Hazard Ratio
11%
Non Small Cell Lung Cancer
11%
Thymus
10%
Thymic Carcinoma
10%
Alogliptin
10%
Epithelioma
10%
Biopsy Technique
9%
Paclitaxel
9%
Aortic Stenosis
9%
Prostate Hypertrophy
9%
Invasive Procedure
9%
Radiation Therapy
9%
Second Cancer
9%
Aortic Valve Disease
9%
Cryotherapy
9%
Neuropathy
9%
Atherosclerotic Plaque
9%
Acute Kidney Injury
9%
Tamsulosin
9%
Debulking Surgery
9%
Cytoreductive Surgery
9%
Retrospective Study
9%
Chemotherapy-Induced Peripheral Neuropathy
8%
Recurrence Free Survival
7%
Arm
7%
Urine Flow Rate
6%
Quality of Life
6%
Cardiovascular System
5%
Adverse Event
5%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
49%
Clinical Trial
45%
Statin (Protein)
34%
Eye Irritation
24%
Aortic Stenosis
15%
Drug Development
14%
Aortic Valve Disease
14%
Dasatinib
14%
Amino Acid Derivative
14%
Maximum Tolerated Dose
14%
Irritable Colon
14%
Warfarin
14%
Malignant Neoplasm
14%
Pravastatin
13%
Pitavastatin
13%
Observational Study
11%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
C Reactive Protein
10%
Lung Cancer
10%
Coronary Artery Atherosclerosis
10%
Leukemia
9%
Hematologic Malignancy
9%
Experimental Animal
9%
Antivitamin K
9%
Adenosine Triphosphate
9%
Thymus Cancer
9%
Thymidine
9%
Tamsulosin
9%
Iron Deficiency
9%
Myositis
9%
Clinical Trial Design
9%
Prostate Hypertrophy
9%
Retrospective Study
9%
Cytarabine
9%
Atrial Fibrillation
9%
Cytomegalovirus
9%
Interstitial Lung Disease
9%
Helicobacter Pylori
9%
Community Pharmacy
9%
Broxuridine
9%
Skin Toxicity
9%
Alzheimer's Disease
9%
Angina Pectoris
9%
Recurrent Disease
9%
Diseases
8%
Anticarcinogen
7%
Combination Drug
7%
Guinea Pig
6%
Prospective Study
6%
Acute Myeloid Leukemia
6%
